American Diabetes Association: NIH, NIDDK aid fight to stop diabetes
ALEXANDRIA, Va. — The National Institutes of Health and the National Institute of Diabetes and Digestive and Kidney Diseases play an important role in discovering innovative ways to address the growing diabetes epidemic in the United States, the American Diabetes Association said at a congressional briefing.
The briefing, "Advancing Discovery: The Role of NIH Research in Fighting Diabetes," was held in conjunction with the Ad-Hoc Group for Medical Research, a coalition of national organizations that support federal funding for the NIH, and cosponsored by the ADA.
The briefing was held as members of Congress are mulling ways to fund federal programs in fiscal year 2012. NIDDK, which is 1-of-27 NIH institutes, is the primary federal agency that conducts research to find a cure for diabetes and improve diabetes care, the ADA said.
BI, Lilly drug reduces blood sugar over long term
LISBON, Portugal — A drug made by Boehringer Ingelheim and Eli Lilly showed "meaningful and durable" reductions in blood sugar in adults with Type 2 diabetes, according to results of a late-stage clinical trial presented Friday at a conference in Europe.
BI and Lilly presented data from their 102-week phase-3 study of Tradjenta (linagliptin) at the European Association for the Study of Diabetes’ 47th annual meeting in Lisbon, Portugal, showing that the drug lowered HbA1C levels by 0.8% over the long term. The drug is marketed in Europe under the name Trajenta.
"These results show that the efficacy achieved by linagliptin is reliable and meaningful in a clinical setting, but also that it is durable over the long term," said David Owens, a medical professor at Cardiff University School of Medicine, in Wales.
In the 2,121-patient study, patients were given Tradjenta, Tradjenta with metformin or Takeda’s Actos (pioglitazone) or Trajdenta with metformin and sulphonylurea.
Emerson Group hires CVS’ Elizabeth Karvonen
WAYNE, Pa. — Former CVS/pharmacy product development manager Elizabeth Karvonen has joined the Emerson Group, where she will work on the beauty and personal care businesses at CVS/pharmacy.
Prior to joining the Emerson Group, Karvonen was a product development manager at CVS/pharmacy, where she developed private-label beauty and personal care products. In her first year, she developed more than 160 private-label products and was responsible for supply chain and logistics for the private-label beauty and personal care categories.